» Articles » PMID: 34266728

Advances in External Beam Radiation Therapy and Brachytherapy for Cervical Cancer

Overview
Specialty Oncology
Date 2021 Jul 16
PMID 34266728
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The standard of care for the definitive treatment of locoregionally advanced cervical cancer is external beam radiation therapy (EBRT) with concurrent chemotherapy followed by a brachytherapy boost. Historically, EBRT was delivered via a two-dimensional technique based primarily on bony landmarks. This gave way to three-dimensional conformal radiation therapy, which allows for dose calculation and adjustment based on individual tumour and patient anatomy. Further technological advances have established intensity-modulated radiation therapy (IMRT) as a standard treatment modality, given the ability to maintain tumoricidal doses to target volumes while reducing unwanted radiation dose to nearby critical structures, thereby reducing toxicity. Routine image guidance allows for increased confidence in patient alignment prior to treatment, and the ability to visualise the daily position of the targets and organs at risk has been instrumental in allowing safe reductions in treated volumes. Additional EBRT technologies, including proton therapy and stereotactic body radiation therapy, may further improve the therapeutic index. In the realm of brachytherapy, a shift from point-based dose planning to image-guided brachytherapy has been associated with improved local control and reduced toxicity, with additional refinement ongoing. Here we will discuss these advances, the supporting data and future directions.

Citing Articles

The role of MRI in radiotherapy planning: a narrative review "from head to toe".

De Pietro S, Di Martino G, Caroprese M, Barillaro A, Cocozza S, Pacelli R Insights Imaging. 2024; 15(1):255.

PMID: 39441404 PMC: 11499544. DOI: 10.1186/s13244-024-01799-1.


Evaluation of cumulative dose distributions from external beam radiation therapy using CT-to-CBCT deformable image registration (DIR) for cervical cancer patients.

Eckrich C, Lee B, Wang C, Light K, Chino J, Rodrigues A J Appl Clin Med Phys. 2024; 26(1):e14538.

PMID: 39365744 PMC: 11713260. DOI: 10.1002/acm2.14538.


A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers.

Seker Karatoprak G, Dumlupinar B, Celep E, Kurt Celep I, Akkol E, Sobarzo-Sanchez E Front Pharmacol. 2024; 15:1423480.

PMID: 39364049 PMC: 11447453. DOI: 10.3389/fphar.2024.1423480.


New Frontiers in Locally Advanced Cervical Cancer Treatment.

Massobrio R, Bianco L, Campigotto B, Attianese D, Maisto E, Pascotto M J Clin Med. 2024; 13(15).

PMID: 39124724 PMC: 11312973. DOI: 10.3390/jcm13154458.


Selenium-Doped Nanoheterojunctions for Highly Efficient Cancer Radiosensitization.

Qiao R, Yuan Z, Yang M, Tang Z, He L, Chen T Adv Sci (Weinh). 2024; 11(29):e2402039.

PMID: 38828705 PMC: 11304322. DOI: 10.1002/advs.202402039.